Combinatorial chemoprevention of intestinal neoplasia

Christopher J. Torrance, Peta E. Jackson, Elizabeth A Montgomery, Kenneth W Kinzler, Bert Vogelstein, Allan Wissner, Maria Nunes, Philip Frost, Carolyn M. Discafani

Research output: Contribution to journalArticle

Abstract

A combination of two drugs afforded remarkable protection from intestinal neoplasia in APC(Min/+) mice, a murine model of human familial adenomatous polyposis (FAP). One of the drugs was sulindac, a prototypical non-steroidal anti-inflammatory drug with established chemopreventative activity. The second drug was EKI-569, a newly developed, irreversible inhibitor of the epidermal growth factor receptor kinase. Although 100% of the untreated APC(Min/+) mice developed ~20 polyps, nearly half the mice treated with these two agents developed no polyps at all. These results suggest a powerful strategy for the chemoprevention of human colonic neoplasia.

Original languageEnglish (US)
Pages (from-to)1024-1028
Number of pages5
JournalNature Medicine
Volume6
Issue number9
DOIs
StatePublished - Sep 2000

Fingerprint

Chemoprevention
Polyps
Pharmaceutical Preparations
Sulindac
Neoplasms
Adenomatous Polyposis Coli
Drug Combinations
Epidermal Growth Factor Receptor
Anti-Inflammatory Agents

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Combinatorial chemoprevention of intestinal neoplasia. / Torrance, Christopher J.; Jackson, Peta E.; Montgomery, Elizabeth A; Kinzler, Kenneth W; Vogelstein, Bert; Wissner, Allan; Nunes, Maria; Frost, Philip; Discafani, Carolyn M.

In: Nature Medicine, Vol. 6, No. 9, 09.2000, p. 1024-1028.

Research output: Contribution to journalArticle

Torrance, CJ, Jackson, PE, Montgomery, EA, Kinzler, KW, Vogelstein, B, Wissner, A, Nunes, M, Frost, P & Discafani, CM 2000, 'Combinatorial chemoprevention of intestinal neoplasia', Nature Medicine, vol. 6, no. 9, pp. 1024-1028. https://doi.org/10.1038/79534
Torrance, Christopher J. ; Jackson, Peta E. ; Montgomery, Elizabeth A ; Kinzler, Kenneth W ; Vogelstein, Bert ; Wissner, Allan ; Nunes, Maria ; Frost, Philip ; Discafani, Carolyn M. / Combinatorial chemoprevention of intestinal neoplasia. In: Nature Medicine. 2000 ; Vol. 6, No. 9. pp. 1024-1028.
@article{0360ceb4647d4cb299f8bc3c8a977430,
title = "Combinatorial chemoprevention of intestinal neoplasia",
abstract = "A combination of two drugs afforded remarkable protection from intestinal neoplasia in APC(Min/+) mice, a murine model of human familial adenomatous polyposis (FAP). One of the drugs was sulindac, a prototypical non-steroidal anti-inflammatory drug with established chemopreventative activity. The second drug was EKI-569, a newly developed, irreversible inhibitor of the epidermal growth factor receptor kinase. Although 100{\%} of the untreated APC(Min/+) mice developed ~20 polyps, nearly half the mice treated with these two agents developed no polyps at all. These results suggest a powerful strategy for the chemoprevention of human colonic neoplasia.",
author = "Torrance, {Christopher J.} and Jackson, {Peta E.} and Montgomery, {Elizabeth A} and Kinzler, {Kenneth W} and Bert Vogelstein and Allan Wissner and Maria Nunes and Philip Frost and Discafani, {Carolyn M.}",
year = "2000",
month = "9",
doi = "10.1038/79534",
language = "English (US)",
volume = "6",
pages = "1024--1028",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Combinatorial chemoprevention of intestinal neoplasia

AU - Torrance, Christopher J.

AU - Jackson, Peta E.

AU - Montgomery, Elizabeth A

AU - Kinzler, Kenneth W

AU - Vogelstein, Bert

AU - Wissner, Allan

AU - Nunes, Maria

AU - Frost, Philip

AU - Discafani, Carolyn M.

PY - 2000/9

Y1 - 2000/9

N2 - A combination of two drugs afforded remarkable protection from intestinal neoplasia in APC(Min/+) mice, a murine model of human familial adenomatous polyposis (FAP). One of the drugs was sulindac, a prototypical non-steroidal anti-inflammatory drug with established chemopreventative activity. The second drug was EKI-569, a newly developed, irreversible inhibitor of the epidermal growth factor receptor kinase. Although 100% of the untreated APC(Min/+) mice developed ~20 polyps, nearly half the mice treated with these two agents developed no polyps at all. These results suggest a powerful strategy for the chemoprevention of human colonic neoplasia.

AB - A combination of two drugs afforded remarkable protection from intestinal neoplasia in APC(Min/+) mice, a murine model of human familial adenomatous polyposis (FAP). One of the drugs was sulindac, a prototypical non-steroidal anti-inflammatory drug with established chemopreventative activity. The second drug was EKI-569, a newly developed, irreversible inhibitor of the epidermal growth factor receptor kinase. Although 100% of the untreated APC(Min/+) mice developed ~20 polyps, nearly half the mice treated with these two agents developed no polyps at all. These results suggest a powerful strategy for the chemoprevention of human colonic neoplasia.

UR - http://www.scopus.com/inward/record.url?scp=0033827119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033827119&partnerID=8YFLogxK

U2 - 10.1038/79534

DO - 10.1038/79534

M3 - Article

VL - 6

SP - 1024

EP - 1028

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 9

ER -